SCHEMBL2118650

SCHEMBL2118650

Cc1ccc(-c2cnco2)cc1NS(=O)(=O)c1cccs1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.55
ALDH1A1 P00352 5/20 0.55
KMT2A Q03164 4/20 0.55
MEN1 O00255 2/20 0.55
MAPT P10636 2/20 0.55
NPC1 O15118 2/20 0.45
GAA P10253 2/20 0.45
GLA P06280 2/20 0.45
RAB9A P51151 1/20 0.45
ATM Q13315 1/20 0.45
TP53 P04637 1/20 0.44
CCR2 P41597 3/20 0.44
TSHR P16473 2/20 0.44
POLB P06746 1/20 0.44
HPGD P15428 2/20 0.43
HSD17B10 Q99714 1/20 0.43
EDNRA P25101 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2119314 0.83 TP53 (0.45) KDM4EALDH1A1KMT2AMEN1MAPT
SCHEMBL2121588 0.80 CYP3A4 (0.46) KMT2AMEN1RAB9ATP53POLB
SCHEMBL9930725 0.79 CCR2 (0.64) KMT2ACCR2POLB
SCHEMBL2117367 0.79 EDNRA (0.46) KMT2ACCR2POLBEDNRA
SCHEMBL2119623 0.78 GHSR (0.45) KDM4EALDH1A1KMT2AMEN1MAPT
SCHEMBL2119222 0.78 ALDH1A1 (0.61) KDM4EALDH1A1KMT2AMEN1MAPT
SCHEMBL2117134 0.77 SLC40A1 (0.46) KMT2AMEN1MAPTPOLBEDNRA
SCHEMBL2118685 0.77 POLB (0.57) ALDH1A1KMT2AMEN1MAPTRAB9A
SCHEMBL2119257 0.77 POLB (0.48) KMT2AMEN1GAARAB9APOLB
SCHEMBL2121436 0.77 POLB (0.51) ALDH1A1KMT2AMAPTRAB9APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095012-A1 TOLUIDINE SULFONAMIDES AND THEIR USE ELARA PHARMACEUTICALS GMBH (DE) 2012-04-19 US disclosed
EP-2382190-A1 TOLUIDINE SULFONAMIDES AND THEIR USE AS-INHIBITORS European Molecular Biology Laboratory (EMBL) (DE) 2011-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095012-A1 TOLUIDINE SULFONAMIDES AND THEIR USE HIF1A, HIF1AN, EGLN3 KDM4E 191/4885ALDH1A1 1063/4885KMT2A 290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.